Loading…
Recombinant long‐acting glyco PEG ylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials
Background The paradigm ™ 2 and 4 phase 3 clinical trials investigated the safety and efficacy of nonacog beta pegol, a recombinant glyco PEG ylated factor IX ( FIX ) with extended half‐life, in previously treated haemophilia B patients. Aim These post hoc analyses investigated the bleeding patterns...
Saved in:
Published in: | Haemophilia : the official journal of the World Federation of Hemophilia 2016-07, Vol.22 (4), p.507-513 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background
The paradigm
™
2 and 4 phase 3 clinical trials investigated the safety and efficacy of nonacog beta pegol, a recombinant glyco
PEG
ylated factor
IX
(
FIX
) with extended half‐life, in previously treated haemophilia B patients.
Aim
These
post hoc
analyses investigated the bleeding patterns in target joints.
Methods
Patients randomized to 40 or 10 IU kg
−1
once weekly prophylaxis who had at least one target joint were included. Baseline demographics and disease‐specific data were collected. Bleeding patterns were assessed, and an International Society on Thrombosis and Haemostasis (
ISTH
) definition of target joints was used.
Results
A total of 67% and 8% of patients in the 40 and 10 IU kg
−1
arm, respectively, did not experience target joint bleeds during the paradigm
™
2 trial. Twenty‐four target joints were recorded in each prophylaxis arm at baseline. During the paradigm
™
2 trial, no bleeds were reported in 17 (71%) and 7 (29%) target joints in the 40 and 10 IU kg
−1
arms respectively. All target joint bleeds in the 40 IU kg
−1
once weekly prophylaxis arm were controlled with a single injection of 40 IU kg
−1
nonacog beta pegol. By the latest
ISTH
definition, 90% and 58% of target joints in the 40 and 10 IU kg
−1
arms, respectively, were no longer considered target joints at the end of the paradigm
™
2 trial. At the end of the paradigm
™
4 extension trial, all target joints in the 40 IU kg
−1
arm were no longer considered target joints.
Conclusion
Routine prophylaxis with 40 IU kg
−1
once weekly nonacog beta pegol has the potential for effective management of target joint bleeds in haemophilia B patients. |
---|---|
ISSN: | 1351-8216 1365-2516 |
DOI: | 10.1111/hae.12902 |